服务平台拥有丰富的技术服务经验，一流的仪器设备，先进的检测手段和严格的质量控制体系，力求为全球药物研发机构提供优质高效的技术服务
背景介绍 Quisinostat, also known asJNJ-26481585, is an orally bioavailable, second-generation, hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. HDAC inhibitor JNJ-26481585 inhibits HDAC leading to an accumulation of highly acetylated histones, which may result in an induction of chromatin remodeling; inhibition of the transcription of tumor suppressor genes; inhibition of tumor cell division; and the induction of tumor cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins. Compared to some first generation HDAC inhibitors, JNJ-26481585 may induce superior HSP70 upregulation and bcl-2 downregulation. 产品介绍 JNJ-26481585, also known as Quisinostat, is a potent pan-HDAC inhibitor. JNJ-26481585 induces histone acetylationand inhibits cancer cell proliferation.
询价背景介绍 Quisinostat, also known asJNJ-26481585, is an orally bioavailable, second-generation, hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. HDAC inhibitor JNJ-26481585 inhibits HDAC leading to an accumulation of highly acetylated histones, which may result in an induction of chromatin remodeling; inhibition of the transcription of tumor suppressor genes; inhibition of tumor cell division; and the induction of tumor cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins. Compared to some first generation HDAC inhibitors, JNJ-26481585 may induce superior HSP70 upregulation and bcl-2 downregulation. 产品介绍 JNJ-26481585, also known as Quisinostat, is a potent pan-HDAC inhibitor. JNJ-26481585 induces histone acetylationand inhibits cancer cell proliferation.
询价背景介绍 Quisinostat, also known asJNJ-26481585, is an orally bioavailable, second-generation, hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. HDAC inhibitor JNJ-26481585 inhibits HDAC leading to an accumulation of highly acetylated histones, which may result in an induction of chromatin remodeling; inhibition of the transcription of tumor suppressor genes; inhibition of tumor cell division; and the induction of tumor cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins. Compared to some first generation HDAC inhibitors, JNJ-26481585 may induce superior HSP70 upregulation and bcl-2 downregulation. 产品介绍 JNJ-26481585, also known as Quisinostat, is a potent pan-HDAC inhibitor. JNJ-26481585 induces histone acetylationand inhibits cancer cell proliferation.
询价背景介绍 Bromodomains have an important role in the targeting of chromatin-modifying enzymes to specific sites, including methyltransferases, HATs and transcription factors and regulate diverse biological processes from cell proliferation and differentiation to energy homeostasis and neurological processes. 产品介绍 I-BET-762 is a small molecule inhibitor of the BET family of bromodomaincontaining proteins. It has been shown to bind to the acetylated lysine recognition motifs on the bromodomain of BET proteins. This binding prevents the interaction of between BET proteins and acetylated histone peptides.
询价背景介绍 Bromodomains have an important role in the targeting of chromatin-modifying enzymes to specific sites, including methyltransferases, HATs and transcription factors and regulate diverse biological processes from cell proliferation and differentiation to energy homeostasis and neurological processes. 产品介绍 I-BET-762 is a small molecule inhibitor of the BET family of bromodomaincontaining proteins. It has been shown to bind to the acetylated lysine recognition motifs on the bromodomain of BET proteins. This binding prevents the interaction of between BET proteins and acetylated histone peptides.
询价背景介绍 Bromodomains have an important role in the targeting of chromatin-modifying enzymes to specific sites, including methyltransferases, HATs and transcription factors and regulate diverse biological processes from cell proliferation and differentiation to energy homeostasis and neurological processes. Optimized to retain excellent BET target potency and selectivity while enhancing the in vivo pharmacokinetics and terminal half-life to enable prolonged in vivo studies. 产品介绍 I-BET151(GSK1210151A) is a BET bromodomain inhibitor. I-BET151 displays potent binding affinity to BRD2, BRD3 and BRD4 with Kd of 0.02-0.1 µM. I-BET151 (0.5 or 5 µM) inhibits the binding of BETs (BRD2, BRD3, BRD4, and BRD9) but not the binding of 23 other bromodomain proteins. I-BET151 also blocks recruitment of BET to chromatin.
询价背景介绍 Bromodomains have an important role in the targeting of chromatin-modifying enzymes to specific sites, including methyltransferases, HATs and transcription factors and regulate diverse biological processes from cell proliferation and differentiation to energy homeostasis and neurological processes. Optimized to retain excellent BET target potency and selectivity while enhancing the in vivo pharmacokinetics and terminal half-life to enable prolonged in vivo studies. 产品介绍 I-BET151(GSK1210151A) is a BET bromodomain inhibitor. I-BET151 displays potent binding affinity to BRD2, BRD3 and BRD4 with Kd of 0.02-0.1 µM. I-BET151 (0.5 or 5 µM) inhibits the binding of BETs (BRD2, BRD3, BRD4, and BRD9) but not the binding of 23 other bromodomain proteins. I-BET151 also blocks recruitment of BET to chromatin.
询价背景介绍 Bromodomains have an important role in the targeting of chromatin-modifying enzymes to specific sites, including methyltransferases, HATs and transcription factors and regulate diverse biological processes from cell proliferation and differentiation to energy homeostasis and neurological processes. Optimized to retain excellent BET target potency and selectivity while enhancing the in vivo pharmacokinetics and terminal half-life to enable prolonged in vivo studies. 产品介绍 I-BET151(GSK1210151A) is a BET bromodomain inhibitor. I-BET151 displays potent binding affinity to BRD2, BRD3 and BRD4 with Kd of 0.02-0.1 µM. I-BET151 (0.5 or 5 µM) inhibits the binding of BETs (BRD2, BRD3, BRD4, and BRD9) but not the binding of 23 other bromodomain proteins. I-BET151 also blocks recruitment of BET to chromatin.
询价背景介绍 Histone H2Ais one of the five main histone proteins involved in the structure of chromatin in eukaryotic cells. Histones are proteins that package DNA into nucleosomes. Histones are responsible for maintaining the shape and structure of a nucleosome. One chromatin molecule is composed of at least one of each core histones per 100 base pairs of DNA. There are five families of histones known to date; these histones are termed H1/H5, H2A, H2B, H3, and H4. H2A is important for packaging DNA into chromatin. Since H2A packages DNA molecules into chromatin, the packaging process will effect gene expression.H2A has been correlated with DNA modification and epigenetics. H2A plays a major role in determining the overall structure of chromatin. Inadvertently, H2A has been found to regulate gene expression. DNA modification by H2A occurs in the cell nucleus. The proteins responsible for nuclear import of H2A protein are karyopherin and importin. Recent studies also show that nucleosome assembly protein 1 is also used to transport of H2A into the nucleus so it can wrap DNA. 产品介绍 Synthetic peptide corresponding to a.a. 107-122 of Histone-H2A, MW= 1762.1.
询价
